United Therapeutics (UTHR) Tops Q1 EPS by 41c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St futures rise as AI stocks rally, crude prices fall
- Oil prices slide to 11-day low on hopes of US-Iran diplomacy, Saudi exports
- Warren Buffett transitions to Berkshire’s chairman emeritus
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- Streamflation drives 39% of Americans to cancel streaming in 6 months
United Therapeutics (UTHR) PT Bumped to $203 at Wedbush Despite Top-Line Miss
April 28, 2015 12:24 PM EDTWedbush analyst Liana Moussatos reiterated an Outperform rating and lifted her price target on United Therapeutics Corp. (NASDAQ: UTHR) from $198 to $203 despite Q1 results which missed on the top line.
"Despite the revenue miss, Q1 net sales for Remodulin of $146.3MM beat consensus... More
